Navigation Links
Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
Date:5/7/2008

WALTHAM, Mass., May 7 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (AMEX: ILI), announced today that it will host a conference call and webcast on Wednesday, May 14, 2008 at 4:30 p.m. ET to review the Company's first quarter 2008 financial results and provide an update on recent corporate developments.

To access the live call, dial 877-627-6555 (domestic) or 719-325-4869 (international). The live webcast will be available on the Investors section of the Company's website, http://www.ilgenetics.com.

Replay access of the teleconference will be available for one week following the call by dialing 888-203-1112 (domestic) or 719-457-0820 (international). The passcode for the replay is 4243283. The webcast will be archived following the call at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (AMEX: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has com
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
2. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
3. Interleukin Genetics Retains Top Life Science Communications Firms
4. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
5. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
6. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
7. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
8. Interleukin Genetics Announces Management and Board Appointments
9. deCODE genetics Announces First Quarter 2008 Financial Results
10. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
11. U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...9 Complete Genomics, a third-generation human gen...n of a report in the journal Science describing ... analysis of sequence data from three complete hum...enomes sequenced on the proof-of-principle genomic...e to $1,726 for 45x coverage for the samples descr...
(Date:11/6/2009)... Myriant Technologies LLC ("Myriant"), a privately...wable bio-chemicals, Uhde Corporation of America a...e of the world,s leading engineering contractors (...ineering, procurement & construction (EPC) of ...enewable feedstocks. The execution of this allian...
(Date:11/6/2009)...-- Intarcia Therapeutics, Inc. delivered two prese...uous delivery of exenatide) program for the treatm...s Technology Meeting in San Francisco, CA: ,, (...1/SFTU126LOGO ) ,, Continuous Subcutaneous De...cose, HbA1c and Reduces Weight in a 28-day Phase 1...
(Date:11/5/2009)... -- DSM Pharmaceutical Products today announced th...ix, Saint Jean D,Illac, France, where DSM will be ...er for Galenix commercial products on a global bas...ness development opportunities co-marketing Galeni...h of Galenix in drug product development and clini...
Breaking Biology Technology:Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...d, CAESAREA, Israel, March 26 Alma Lasers Ltd., ...nd radiofrequency systems,announces important deve...hich is being litigated in the United States Distr...e U.S. Patent and Trademark Office in,Alexandria V...menis,s,patents that are at issue in the litigatio...
...pril 1, 2008, LEVERKUSEN, Germany, and PITTSBURGH...ate MEDRAD, Inc. announced,today that it has succe...ding shares of common stock of Possis Medical, Inc...as advised MEDRAD that, as of the expiration,of th...ay, March 25, 2008,a total of 14,951,550 Possis Me...
...h CyberKnife System to Date, SUNNYVALE, Calif., M...global leader in the field of radiosurgery,announc...fe centers,worldwide are now treating lung cancer ...*. The number of lung cancer patients is growing,s...uals receiving,CyberKnife treatments to date., Lu...
Other Biology Technology:U.S. PTO Reexamining Lumenis Patents 2Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period 2Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period 3CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide 2CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide 3CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide 4
(Date:11/4/2009)..., 2009 Childhood obesity in the United States is ...fourth of advertising on daytime and prime time te...uing questions about the role television plays in ... the Journal of Nutrition Education and Behavior ...ight be a large contributor to the problem. , Re...
(Date:11/4/2009)...., Oct. 19 Spectros, developer and...aging devices which shed light on life-threatening...usive distribution deals for both its T-Stat®...ered include Australia, New Zealand, The Netherla...y, France, Spain, Portugal, Poland, Greece, Turkey...
(Date:11/4/2009)... What,s the cost of saving a teenag...th resulting from prescription medication abuse, t... however, may be unaware that the lock-boxes they,...he ticking timebomb of prescription drugs. That,s ...ty medical supplies, has formed an exclusive partn...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Spectros Signs New International Distribution Deals 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3New biomarker method could increase the number of diagnostic tests for cancer 9054 1New biomarker method could increase the number of diagnostic tests for cancer 9054 2New biomarker method could increase the number of diagnostic tests for cancer 9054 3New biomarker method could increase the number of diagnostic tests for cancer 9054 4LodgeNet Interactive Announces Completion of Offering of 2457 5 Million of Convertible Preferred Stock 50318 1LodgeNet Interactive Announces Completion of Offering of 2457 5 Million of Convertible Preferred Stock 50318 2LodgeNet Interactive Announces Completion of Offering of 2457 5 Million of Convertible Preferred Stock 50318 3LodgeNet Interactive Announces Completion of Offering of 2457 5 Million of Convertible Preferred Stock 50318 4Oncology Groups Pharmaceutical Services Agreement Enhances Efficiency of Drug Management Program 50315 1Oncology Groups Pharmaceutical Services Agreement Enhances Efficiency of Drug Management Program 50315 2Oncology Groups Pharmaceutical Services Agreement Enhances Efficiency of Drug Management Program 50315 3
...transplant patients reject their new organs requir...accept or reject each other. Xavier Fernndez-Busqu...y of Barcelona, has found the perfect ally in this...ies that grows abundantly from just north of Cape ...icrociona prolifera) has a cell-to-cell recognitio...
... water is a scene with which we,re all familiar. Y...rable amount of time in the water–polar bears, sea...a thick layer of body fat to keep warm. They rely,...ir fur and the densely packed layer of specially a...scopy and polarizing light microsopy, John W. Weis...
... water is a scene with which we,re all familiar. Y...rable amount of time in the water–polar bears, sea...a thick layer of body fat to keep warm. They rely,...ir fur and the densely packed layer of specially a...scopy and polarizing light microsopy, John W. Weis...
Other Biology News:Simple sea sponge helps scientists understand tissue rejection 2Genome Sequence for Haemophilus Influenzae Completed 2Genome Sequence for Haemophilus Influenzae Completed 3Otter adaptations: How do otters remain sleek and warm 2Otter adaptations: How do otters remain sleek and warm 3
Goat Anti-ZBP-89 (S-15) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Enolase from baker's yeast (S. cerevisiae) from Sigma-Aldrich
UNOsphere S Support, 100 ml from Bio-Rad
Baker's yeast (S. cerevisiae) Phosphoglucose isomerase from Sigma-Aldrich
Biology Products: